# Pacira BioSciences share price today (Pacira BioSciences, Inc., PCRX)

> Pacira BioSciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. PCRX · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/pcrx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $36.39 (+70.2% in a year)
- P/E: 103.5× (lower than 53% of the last 1 year)
- Revenue (Jun 2026): $192 M (+6.2% on a year ago)
- Profit (Jun 2026): $4.7 M
- Operating margin: 6.2% (+1.2 points on a year ago)
- ROE: 1%, FY25
- ROIC: 3.2%, against a 5.1% cost of capital: −1.9 points
- Profit that came in as cash: 696%, last 3 years

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Pacira BioSciences share price today? Pacira BioSciences, Inc.'s share price was $36.39 at the close on 3 November 2026. That is 45.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $19 and $36, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 5 weeks in a row. Over the last 1 year the share price moved +59% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Pacira BioSciences pay? Pacira BioSciences, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Pacira BioSciences on? Pacira BioSciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Pacira BioSciences profitable? Pacira BioSciences, Inc. earned $4.7 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was $7.0 M. Over 4 years profit has grown −36.0% a year on average. That is 2.4% of the quarter's revenue. The same quarter a year earlier lost $4.8 M. 2 of the last 12 reported quarters were loss-making. ## How much revenue does Pacira BioSciences make, and is it growing? Pacira BioSciences, Inc. reported $192 M of revenue in the Jun 2026 quarter, +6.2% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 4 years it has grown 7.6% a year on average. The last full year, FY25, came in at $726 M. The last four reported quarters add to $746 M. FY25 revenue was $726 M, +3.6% on the year before. Recent pace: the last four quarters grew +5.7% on average, against 7.6% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +5.7%, against +4.0% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Pacira BioSciences keep? Pacira BioSciences, Inc.'s operating margin was 6.2% in the Jun 2026 quarter, 1.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between 4.6% and 16.6%. The latest quarter is within that range. Why the margin moved: operating margin changed +1.2 percentage points on the year while gross margin changed −0.4 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Pacira BioSciences' profit turning into cash? Over the last 3 years, 696% of Pacira BioSciences, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $152 M of operating cash against $7.0 M of profit. After $15.3 M of spending on assets, $137 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Pacira BioSciences' cash go? Pacira BioSciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $41.1 M on assets over the last 3 years. Averaged over those years that is 1.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $41.1 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Pacira BioSciences' P/E ratio, and how does it compare with its own history? Pacira BioSciences, Inc.'s P/E is 103.5×, in the middle of its own history: higher than 47% of past readings. Its usual P/E (the middle reading) is 105.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Pacira BioSciences business getting better or worse? Pacira BioSciences, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Pacira BioSciences earn on its capital? Pacira BioSciences, Inc. earned a ROE of 1% in FY25. That is up from a low of −13% in FY24. Its return on capital used (ROIC) is 1.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 1.0% net margin and 0.57× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 1.0% net margin × 0.57× asset turnover × 1.82× leverage (assets divided by equity) ≈ 1.0% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 3.2% − 5.1% = −1.9 percentage points. The 5.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 3.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 1.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Pacira BioSciences have too much debt? Pacira BioSciences, Inc. has total debt of $412 M against shareholder equity of $672 M as of Jun 2026, so its debt is 0.61× its equity. Year by year, that ratio went from 1.55 in FY21 to 0.60 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Pacira BioSciences shareholding pattern? 10.9% of Pacira BioSciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 1.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Pacira BioSciences from balance-sheet trouble? For Pacira BioSciences, Inc., the Z-score is 2.00. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.00 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Pacira BioSciences rank in its industry? There is no score against its industry: Pacira BioSciences, Inc. is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Pacira BioSciences compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Pacira BioSciences in size? Pacira BioSciences is the 30th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: ANI Pharmaceuticals, Inc., Phibro Animal Health Corporation and Eton Pharmaceuticals, Inc. Just below it: Cronos Group Inc., Amphastar Pharmaceuticals, Inc. and Harrow, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) $1.5 billion
2. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) $1.5 billion
3. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) $1.5 billion
4. Pacira BioSciences, Inc. $1.5 billion
5. [Cronos Group Inc.](https://www.sectoralpha.in/us/stocks/cron) $1.3 billion
6. [Amphastar Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amph) $1.2 billion
7. [Harrow, Inc.](https://www.sectoralpha.in/us/stocks/hrow) $1.1 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [agilon health, inc.](https://www.sectoralpha.in/us/stocks/agl) $1.5 billion · Medical Care Facilities
2. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) $1.5 billion · Drug Manufacturers - Specialty & Generic
3. Pacira BioSciences, Inc. $1.5 billion
4. [Lightspeed Commerce Inc.](https://www.sectoralpha.in/us/stocks/lspd) $1.5 billion · Software - Application
5. [Global Ship Lease, Inc.](https://www.sectoralpha.in/us/stocks/gsl) $1.4 billion · Marine Shipping

## What else do people ask about Pacira BioSciences? ### What were Pacira BioSciences's latest quarterly results? Pacira BioSciences, Inc. reported revenue of $192 M and net profit of $4.7 M for the Jun 2026 quarter. Earnings per share were $0.12. The operating margin was 6.2%, 1.2 percentage points higher than a year earlier (as of 3 November 2026). ### What is Pacira BioSciences's market cap? Pacira BioSciences, Inc.'s market capitalisation is $1.5 B at a stock price of $36.39. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Pacira BioSciences performing? Pacira BioSciences, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 5 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Pacira BioSciences's stock price go up? This page does not forecast Pacira BioSciences, Inc.'s stock price. What it shows instead: the stock price is $36.39. Its P/E of 103.5× is higher than 47% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Pacira BioSciences in its business cycle? Pacira BioSciences, Inc.'s FY25 operating margin was 4.6%, against a 5-year range of 4.6% to 16.6%: the low end of its own range, which is often where recoveries start. The latest quarter was 6.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Pacira BioSciences story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Pacira BioSciences a stock worth studying right now? What the numbers show: Pacira BioSciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.